Pre-made Anetumab benchmark antibody ( Whole mAb ADC, anti-MSLN therapeutic antibody, Anti-MPF/SMRP Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Anetumab biosimilar, Whole mAb ADC, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Anetumab ravtansine, here referred to as BAY 94-9343, a novel ADC consisting of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4 via a disulfide-containing linker.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-025-1mg	1mg	Inquiry
GMP-Bios-ab-025-10mg	10mg	Inquiry
GMP-Bios-ab-025-100mg	100mg	Inquiry
GMP-Bios-ab-025-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Anetumab biosimilar, Whole mAb ADC, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody
INN Name	Anetumab
Target	MSLN
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA)
Conditions Approved	na
Conditions Active	Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer;Malignant thymoma
Conditions Discontinued	Fallopian tube cancer;Peritoneal cancer
Development Tech	MorphoSys HuCAL Phage Display